Have the following Open Offers:
The o2h human health funds invest in early-stage biotech therapeutic companies focused on novel drug discovery along with enabling services, tools and AI technologies that can support new medicines. o2h Ventures was launched in 2018 to provide pre-seed and seed capital to Great British biotech innovations. To date, the fund and pre-fund have invested in over 35 companies, several of which have now raised significant funds from overseas, listed and built game-changing drugs to benefit human health.
We have two open funds:
- The o2h human health SEIS Fund
- The o2h human health EIS knowledge-intensive Fund
The o2h human health EIS knowledge-intensive fund
This is our flagship fund and was the first HMRC-approved Knowledge-intensive fund that will invest in EIS-qualifying knowledge-intensive companies. Investing in a Knowledge-intensive EIS fund will provide greater predictability of the year in which EIS relief can be claimed as well as other benefits over and above investing in a non-HMRC-compliant EIS fund. We have two closes per year on 31st October. The minimum investment is £25k.*
The o2h human health SEIS fund
Our SEIS invests into SEIS qualifying Pre-Seed and Seed stage biotech therapeutics companies. These can provide greater tax benefits than an EIS investment, however, usually this is first money into a company so likely to also have a higher risk profile. We have quarterly closing with a £10K min investment. *
Contact us on – invest@o2h.com
For more information please visit www.o2hventures.com and watch the Meet the Manager video here.